Editas Medicine reported its financial results for the third quarter of 2024 on November 4, 2024. The Company's cash, cash equivalents, and marketable securities totaled $265.1 million as of September 30, 2024.
The Company expects its existing cash, cash equivalents, and marketable securities, combined with the upfront cash payment from DRI and retained portions of Vertex payments, to fund operating expenses and capital expenditures into the second quarter of 2026. Editas Medicine also announced it achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using its proprietary targeted LNP.
The net loss for the third quarter of 2024 was $62.1 million. Editas Medicine is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting in December.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.